CCL5 evokes calcium signals in microglia through a kinase-, phosphoinositide-, and nucleotide-dependent mechanism.
Microglia, the resident macrophages of the CNS, are responsible for the innate immune response in the brain and participate in the pathogenesis of certain neurodegenerative disorders. Chemokines initiate activation and migration of microglia. The beta-chemokine CCL5 induces an elevation in intracellular calcium concentration ([Ca(2+)](i)) in human microglia. Here, we examined the signal transduction pathway linking activation of chemokine receptor CCR5 to an elevation in [Ca(2+)](i) in cultured microglia by using pharmacological approaches in combination with Fura-2-based digital imaging. The CCL5-induced response required Janus kinase (Jak) activity and the stimulation of an inhibitory G protein. Multiple downstream signaling pathways were involved, including phosphatidylinositol 3-kinase (PI3K), Bruton's tyrosine kinase (Btk), and phospholipase C (PLC)-mediated release of Ca(2+) from inositol 1,4,5-trisphosphate (IP(3))-sensitive stores. Activation of both the kinase and the lipase pathways was required for eliciting the Ca(2+) response. However, the majority of the [Ca(2+)](i) increase was derived from sources activated by NAD metabolites. Cyclic ADP-ribose (cADPR) evoked Ca(2+) release from intracellular stores, and ADPR evoked Ca(2+) influx via a nimodipine-sensitive channel. Thus, a multistep cascade couples CCR5 activation to Ca(2+) increases in human microglia. Because changes in [Ca(2+)](i) affect chemotaxis, secretion, and gene expression, pharmacologic modulation of this pathway may alter inflammatory and degenerative processes in the CNS.
Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA.
C R
CR
Shideman
S
S
Hu
P K
PK
Peterson
S A
SA
Thayer
D000077329:Agammaglobulinaemia Tyrosine Kinase; D002118:Calcium / Q000378:metabolism; D015220:Calcium Channels / Q000187:drug effects / Q000378:metabolism; D020013:Calcium Signaling / Q000187:drug effects / Q000276:immunology*; D002478:Cells, Cultured; D018946:Chemokine CCL5; D019742:Chemokines, CC / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D036563:Cyclic ADP-Ribose / Q000378:metabolism; D004660:Encephalitis / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000378:metabolism; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology*; D007157:Immunologic Surveillance / Q000276:immunology*; D015544:Inositol 1,4,5-Trisphosphate / Q000378:metabolism; D053613:Janus Kinase 1; D017628:Microglia / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D009243:NAD / Q000378:metabolism; D009410:Nerve Degeneration / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D019713:Receptors, CCR5 / Q000819:agonists / Q000276:immunology* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology / Q000502:physiology; D010738:Type C Phospholipases / Q000378:metabolism
C483024:CCL5 protein, human; D015220:Calcium Channels; D018946:Chemokine CCL5; D019742:Chemokines, CC; D019713:Receptors, CCR5; D009243:NAD; D036563:Cyclic ADP-Ribose; D015544:Inositol 1,4,5-Trisphosphate; D019869:Phosphatidylinositol 3-Kinases; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human; C507904:JAK1 protein, human; D053613:Janus Kinase 1; D010738:Type C Phospholipases; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D002118:Calcium